Selection of Adult Unrelated Hematopoietic Stem Cell Donors: Beyond HLA  by Confer, Dennis L. et al.
From the
sota;
Schoo
Financial d
Correspon
Natio
100, M
 2010 Am
1083-8791
doi:10.101
S8Selection of Adult Unrelated Hematopoietic Stem
Cell Donors: Beyond HLA
Dennis L. Confer,1 Linda K. Abress,1 Willis Navarro,1 Alejandro Madrigal2HLA matching is the dominant controllable donor-recipient factor determining the outcome of adult unre-
lated donor hematopoietic cell transplantation. Beyond HLA, donor selection is often based on donor char-
acteristics such as age, sex, parity, cytomegalovirus (CMV) serostatus, and ABO blood type. The published
evidence to suggest these additional factors are important determinants of survival is weak and is sometimes
conflicting. Other factors may be more important for optimal donor selection than the traditional non-HLA
factors. These include the donor’s geographic location, the performance history of the groups managing the
donor, a priori knowledge of the donor’s willingness/availability, and others. Implementation of tools to ex-
pose this additional donor-related information could significantly alter and aid unrelated donor selection
practices.
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In unrelated donor (URD) hematopoietic stem cell
transplantation (HSCT), the importance of HLA
matching is well established [1–6]. A recent publica-
tion of National Marrow Donor Program (NMDP)
URD HSCT retrospective observations showed that
allele-level matching for HLA-A, B, C, and DRB1
was associated with the best overall survival (OS)[2].
A total of 3857 donor-recipient pairs typed at the al-
lele-level for HLA-A, B, C, DRB1, DQA1, DQB1,
DPA1, and DPB1 were included in this analysis. The
study showed that HLA mismatching at HLA-DQ
or DP did not have an impact on survival. At the other
loci, a single mismatch reduced the expected survival at
1 year by 9%. Furthermore, there was no evident
difference between allele-level and antigen-level
mismatches; that is, an allele-level mismatch, except
perhaps at HLA-C, was just as detrimental as an
antigen-level mismatch. In evaluating individual loci,
mismatches at HLA-A and DRB1 appeared to have
a greater negative impact than those at HLA-B and C.1National Marrow Donor Program, Minneapolis, Minne-
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6/j.bbmt.2009.10.031The study by Lee et al. [2] contrasted with an
earlier evaluation of NMDP data reported by Flomen-
berg et al. [1]. In the Flomenberg et al. analysis, which
included 1874 donor-recipient pairs evaluated with al-
lele-level HLA matching, antigen mismatches were as-
sociated with worse survival than were allele-level
mismatches. Differences in the findings of these 2
studies, which included overlapping datasets, likely
relate to how the analyses were conducted. In the
Flomenberg et al. study, the effect of mismatching at
a single locus was assessed by multivariable analysis
of mismatching at other loci. In the more recent study,
with more than twice as many pairs available for anal-
ysis, mismatching at any locus was compared to pairs
that were matched at every locus.
The analyses by Flomenberg and Lee and their
colleagues largely evaluated transplants using bone
marrow (BM) as the stem cell source. In the current
NMDP experience, .70% of adult donations are
peripheral blood stem cells (PBSC). A recent analysis
of PBSC-specific transplantation outcomes has sug-
gested that the impact of HLA mismatching may differ
from the observations in BM transplantation
(BMT)[7]. In this analysis by Woolfrey et al. [7], which
was conducted similarly to the Lee et al. study by
comparing mismatches to fully matched pairs, single-
antigen mismatches were more detrimental than single
allele mismatches. Among individual loci, HLA-C an-
tigen mismatches were more detrimental for survival
than others. The inability to see an effect at the allele
level or at the non-HLA-C loci may have been limited
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categories.NON-HLA FACTORS IN URD DONOR
SELECTION
Although some patients may have very limited
numbers of potential donors, others will have many
choices. How should multiple similarly HLA-matched
donors be prioritized? These factors include donor-
specific factors, for example, age, sex, cytomegalovirus
(CMV)-serostatus, as well as ‘‘system-specific’’ ones,
such as geographic location, evidence of engagement
in the program, and performance of the managing
donor center.
Kollman et al. [8], in 2001, evaluated the influence
of non-HLA donor factors in a retrospective analysis
of NMDP-facilitated transplants. Outcomes evaluated
were OS, disease-free survival (DFS), relapse, engraft-
ment, acute graft-versus-host disease (aGVHD), and
chronic GVHD (cGVHD). The analysis included
6978 transplantations performed between 1987 and
1999. HLA matching in this study was evaluated at
the antigen level for HLA-A and B and the allele-level
for HLA-DRB1. HLA-C matching was not consid-
ered. HLA matching was the dominant factor affecting
survival, DFS, engraftment, and aGVHD. No donor
factor affected relapse, and only HLA-matching influ-
enced engraftment. Younger donors, however, were
associated with lower rates of aGVHD and cGVHD.
Donor race, CMV serostatus, and ABO blood type
did not affect rates of GVHD. Male donors and nullip-
arous females were associated with lower risks for
cGVHD. A single pregnancy was less important than
2 or more pregnancies. No effect of parity was seen
in aGVHD. In addition to HLA-matching, younger
donor age also improved OS and DFS. For each de-
cade of increase in donor age beyond age 18 years,
the relative risk for recipient mortality was 1.10
(95% confidence interval [CI] 5 1.06, 1.14, P \
.0001). Although CMV-seropositive recipients had
lower OS, donor CMV serostatus had no impact
upon survival of either CMV-negative or CMV-
positive recipients. Male and female recipients sur-
vived similarly and neither was affected by the sex of
the donors.
In the more recent study by Lee et al. [2], no donor
factor beyond HLA-matching affected recipient sur-
vival. The donor factors evaluated included age, sex,
parity, and CMV serostatus. Several factors may
account for the different findings between these 2
studies. Although the Kollman et al. study included
more donor-recipient pairs, HLA matching was not
as well delineated. The Kollman et al. study also exam-
ined donor age by decade, whereas the Lee et al. study
examined larger groupings (15 year’s span in each).
Finally, the Kollman et al. study included recipientstransplanted for nonmalignant conditions, whereas
Lee et al. was restricted to leukemias and myelodysplas-
tic syndromes (MDS). Both studies included a high
percentage (35% to 40%) of patients with CML, which
is today an uncommon indication for HSCT.
An earlier study found that donor CMV serology
did not affect the incidence of CMV infection in recip-
ients [9], whereas a more recent European Blood and
Marrow Transport (EBMT) analysis showed benefit
to CMV-positive patients transplanted from CMV-
positive unrelated donors [10]. The relationship
between donor parity and aGVHD and cGVHD has
also been examined by others with findings of both
negative impact [11–13] and no impact [14]. Much of
the data reviewed here is based on transplants per-
formed before the new millennium. An updated analy-
sis including recent NMDP transplants is in process.BEYOND THE TRADITIONAL NON-HLA
FACTORS IN DONOR SELECTION
The timely application of allogeneic HSCT is of-
ten essential to optimize transplant outcomes. In
fact, within the NMDP, the most common reason
for canceled searches that are already underway is pa-
tient death or inability to proceed to transplant. A key
element in the rapid facilitation of unrelated allogeneic
HSCT is the availability of a suitable donor. However,
several types of challenges exist that can delay or block
the availability of a donor. (Availability in this context
means locatable, interested in continuing, medically fit
after a brief interview, and immediately able to pro-
ceed, for example, not pregnant).
Factors Related to the Donor
Because some donors have been on the registry for
a number of years, and because the donor population
in general is relatively mobile, it is not uncommon
for the donor location information within the registry
to be out of date, resulting in delays as the donor is lo-
cated. Moreover, some donors face significant per-
sonal and socioeconomic challenges that can impede
their ability to serve as a donor. Others have had
a change in their own medical history since registra-
tion that may preclude serving as a donor. Still others
have reexamined their willingness to serve as a donor
and have decided not to participate. The total number
of donors in the NMDP registry now exceeds 8 mil-
lion; therefore, the frequency in which the registry
has been updated to reflect changes affecting donor
availability is not optimal.
Factors Related to the Donor Selection and
Evaluation Process
The NMDP has been exploring how changes in
business processes and information technology can
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work-up, and coordination of collection. Preliminary
estimates suggest that changes in the current operating
model could cut the time by more than half. The find-
ings of that effort are currently under evaluation.
Moreover, the operating efficiency of the donor center
and its associated collection sites coordinating the
affects to evaluate and medically clear the donor also
affects the time from confirmatory typing to donation.
Mitigation of Delays
One mechanism that can markedly improve donor
availability is to prescreen potential donors identified
in an active search as most likely to be requested. A
6-month pilot exploring this approach was tested by
the NMDP in 2006-2007. In the project, 4798 poten-
tial donors were screened; 1968 were deferred (40%)
and 2308 (48%) were available to proceed. At confir-
matory typing (CT) or high-resolution typing, 89%
of prescreened donors were available, compared to
52% of donors not prescreened. The median time to
resolution of a high-resolution/confirmatory typing
request fell from 10 days for the unscreened donors
to 7 days for the prescreened donors. Thus, the effort
to enhance the speed of donor availability was success-
ful, but was also highly labor intensive and very costly.
Nevertheless, as a proof of principle, it is clear that do-
nor contact improves the availability and reliability of
donors. A fully implemented electronic communi-
cation system could render this approach feasible
and cost effective. Additional approaches to proac-
tively engaging registered donors are also under
consideration.
Another means to improve donor processing has
been addressed at the level of the donor center. A 4-
tiered donor center ranking system has been created
that measures performance in 5 areas: percent of CT
specimens collected within 10 days; Caucasian donor
availability for CT; minority donor availability for
CT; length of time from donor workup request to clear-
ance; and donor satisfaction after donation. The tiered
system was created to measure performance and to in-
centivize improvement. As this system matures, it is ex-
pected to drive the sharing of best practices and
improvements in overall donor center performance.
Donor Readiness
It is the goal of the NMDP to facilitate donation by
the best possible HLA matched unrelated donor as
rapidly as possible for transplant centers and their pa-
tients. To that end, the NMDP is considering ways to
provide more predictive information about donors
that goes beyond HLA typing to incorporate an assess-
ment of donor readiness. Such a metric or indicator
will be useful for transplant centers for predicting the
likelihood of a donor being promptly available asthey select donors. Significant work remains to be
done, however, for this to become a reality. A predic-
tive algorithm will need to be developed, tested, and
validated. User input of the algorithm will then need
to be obtained to assure optimal presentation of the
data and to ensure appropriate use and interpretation.
Although challenges to this goal remain, the fruits of
this labor will be enhanced speed of donor availability
and improved transplant outcomes.SUMMARY
Traditional non-HLA factors considered in the
selection of unrelated donors for HSCT include age,
sex, parity, CMV serostatus, and ABO blood type.
Published evidence suggests these donor factors exert
weak effects, if any, on the outcomes of HSCT. In
the future, donor-related factors that predict for rapid,
efficient, and successful searches may supplement or
replace the traditional non-HLA factors. Such predic-
tors include currency of the donor’s contact informa-
tion and evidence of their engagement and
motivation, as well as indicators of donor center and
collection site performance.ACKNOWLEDGMENTS
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